Clinical Trials Logo

Myeloid Malignancies clinical trials

View clinical trials related to Myeloid Malignancies.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04778410 Completed - Clinical trials for Myeloid Malignancies

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Start date: June 28, 2021
Phase: Phase 2
Study type: Interventional

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).

NCT ID: NCT03270748 Completed - Clinical trials for Myeloid Malignancies

Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

GITMO-PHYLOS
Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies.

NCT ID: NCT01731951 Completed - Clinical trials for Primary Myelofibrosis

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Start date: October 29, 2012
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.